Hepatitis C
EASL 2020 ("final update of the series") and the AASLD/IDSA 2023 guidance update agree: treat everyone with a pangenotypic DAA.
Clinical pearls
- Diagnosis: anti-HCV antibody, then HCV RNA to confirm active infection.
- Glecaprevir/pibrentasvir 8 weeks or sofosbuvir/velpatasvir 12 weeks, without genotyping.
- Decompensated cirrhosis: sofosbuvir/velpatasvir + ribavirin 12 weeks; no protease inhibitors.
- Cirrhosis after SVR: HCC surveillance continues for life.